Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

US7208161B1 · kind B1 · utility

Assignee

• THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · US

Inventors

• Brian R. Murphy · Bethesda, US
• Peter L. Collins · Kensington, US
• Anna P. Durbin · Takoma Park, US
• Mario H. Skiadopoulos · Potomac, US
• Tao Tao · Bethesda, US

Key dates

• Filing date: May 22, 1998
• Grant date: Apr 24, 2007
• Expiry date: May 22, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18661
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.